Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

ept.  Patients should be monitored for changes in their lipid profiles and provided with medical treatment if warranted.  Hypersensitivity reactions associated with rilonacept administration have been rare.  Please see the full Prescribing Information for ARCALYST® (rilonacept), available online at www.regeneron.com/ARCALYST-fpi.pdf.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST  Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing dr
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... letter is being released by CEL-SCI Corporation (NYSE Alternext ... Shareholders: , I am writing today to provide you with ... on our plans for dealing with the current financial downturn. ... year of meaningful accomplishments which put CEL-SCI in a valuable ...
... Md., Feb. 19 Hospital associations in 10 ... program to test methods of reducing central-line associated ... (ICUs), according to HHS, Agency for Healthcare Research ... Nebraska, North Carolina, Ohio, Pennsylvania, Texas, and Washington. ...
Cached Medicine Technology:CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 510-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 210-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs 3
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... National Dementia Screening Policy , , ... the nation faces a public health crisis related to ... the Alzheimer,s Foundation of America (AFA) disputes an ongoing ... The report shatters unsubstantiated criticism and instead emphasizes the ...
... Non-Contact Medical Device Innovations - the Future of Patient ... in Outer Space , , ... Noninvasive Medical Technologies, Inc. (NMT), a medical device company ... for military and civilian medical use, today announced that ...
... /PRNewswire-Asia-FirstCall/ -- China Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext ... that the Company is expanding its herbal-based,"12 Ways" ... markets in Mainland China. , ... its "12 Ways" brand of cosmetics products,to eleven ...
... PatentStorm, the searchable website of millions of U.S. patents, has expanded ... applications. PatentStorm has also completed a host of other improvements, making ... ... Washington, DC (PRWEB) December 9, 2008 -- PatentStorm ...
... China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Sky One ... (Nasdaq: CSKI ), a leading,fully integrated ... of China ("PRC"), announced today that its subsidiary,Peng ... production approval from the State Food and Drug ...
... for Low-dose, Weekly Contraceptive Patch to be Presented at ACOG ... , PRINCETON, N.J., Dec. 9 Agile ... products, today announced that two abstracts from Phase 2 studies ... by the American College of Obstetricians and Gynecologists Annual ...
Cached Medicine News:Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 2Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 3Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 4Health News:U.S. Air Force Awards Noninvasive Medical Technologies $2.4 Million Contract 2Health News:U.S. Air Force Awards Noninvasive Medical Technologies $2.4 Million Contract 3Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 2Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 3Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 4Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 2Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 4
... a simple click of the mouse ... mouse cursor to the desired position ... slide and the magnified image is ... Interface (GUI) enables one-click operation of ...
... new Eclipse TS100 is an ... microscope. This high quality tool ... mechanics and increased stability - ... rigid vibration resistant design that ...
Carbide drill bits, cutters, side cutting. Available in various sizes....
... the enclosed polaroid glasses, these polarized ... devise for near point stereopsis which ... perception, the images appear to pop ... test includes circle patterns for depth ...
Medicine Products: